The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
mRNA is not just the basis of new COVID-19 vaccines. mRNA is also a versatile technology for the development and manufacturing of new medicinal product candidates such as cancer. As cancer is also a global health threat, BioNTech aspires to develop individualized cancer treatments. The manufacturing process behind mRNA-based cancer vaccine candidates is equivalent to mRNA-based the company’s COVID-19 vaccine. The vaccine manufacturing approaches mainly differs in the required quantity, e.g. a few microgram of mRNA for the individualized vaccine candidates compared to hundreds of kilograms for a pandemic supply. The new technology allowed not only developing a new COVID-19 vaccine in a record time but also to quickly ramp-up the manufacturing facilities to supply billions of doses. The presentation will reveal key elements that make mRNA such a powerful technology and that define the facility set-up of tomorrow already today, for both: individualized medicines as well as for large volume medical products such as vaccines against infectious diseases.
Speaker(s):
David
Estapé,
PhD,
Technology Manager Biotechnology,
CRB Group GmbH